Related Experiment Video

Updated: Mar 21, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.0K

Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway

Xiaomin Ma1, Pengbo Guo1, Yumin Qiu1

  • 1Department of Immunology, Shandong University School of Medicine, Jinan 250012, China.

Oncotarget
|May 12, 2016
PubMed

Insights

Absent in melanoma (AIM2) protein levels are decreased in liver cancer, suppressing tumor growth by inhibiting the mTOR-S6K1 pathway. Restoring AIM2 may offer a new therapeutic strategy for hepatocellular carcinoma (HCC).

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Absent in melanoma (AIM2) is an interferon-inducible HIN-200 protein family member with roles in immunity and cancer.
  • The specific function of AIM2 in hepatocellular carcinoma (HCC) development is not well understood.

Purpose of the Study:

  • To investigate the role of AIM2 in hepatocellular carcinoma (HCC) progression.
  • To explore AIM2's potential as a therapeutic target for liver cancer.

Main Methods:

  • Analysis of AIM2 expression in HCC tissues.
  • Overexpression and knockdown of AIM2 in HCC cell lines.
  • Investigation of the mammalian target of rapamycin (mTOR)-S6K1 signaling pathway.
  • Treatment with the mTOR inhibitor rapamycin.

Main Results:

  • AIM2 expression is significantly reduced in HCC tissues, correlating with advanced tumor progression.
  • AIM2 overexpression suppresses HCC cell proliferation, colony formation, and invasion by inhibiting the mTOR-S6K1 pathway.
  • AIM2 deficiency activates the mTOR-S6K1 pathway, promoting HCC progression.
  • Rapamycin treatment confirmed the role of the mTOR pathway in AIM2-deficient HCC.

Conclusions:

  • AIM2 functions as a tumor suppressor in hepatocellular carcinoma (HCC).
  • AIM2 deficiency promotes HCC through activation of the mTOR-S6K1 pathway.
  • AIM2 represents a potential therapeutic target for liver cancer gene therapy, with mTOR pathway suppression offering a treatment avenue for AIM2-deficient cancers.
Keywords:
absent in melanoma 2hepatocellular carcinomainflammasomemammalian target of rapamycintumor progression

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K